✦ LIBER ✦

Low-Dose N-Butyldeoxynojirimycin (OGT 918) for Type I Gaucher Disease

✍ Scribed by Rene Heitner; Deborah Elstein; Johannes Aerts; Sonja van Weely; Ari Zimran

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low-Dose N-Butyldeoxynojirimycin (OGT 91

✍ Rene Heitner; Deborah Elstein; Johannes Aerts; Sonja van Weely; Ari Zimran 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 7 KB

Sustained therapeutic effects of oral mi

✍ D. Elstein; C. Hollak; J. M. F. G. Aerts; S. van Weely; M. Maas; T. M. Cox; R. H 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 238 KB

Novel oral treatment of Gaucher's diseas

✍ Timothy Cox; Robin Lachmann; Carla Hollak; Johannes Aerts; Sonja van Weely; Mart 📂 Article 📅 2000 🏛 The Lancet 🌐 English ⚖ 97 KB

Individualised low-dose alglucerase ther

✍ C.E.M. Hollack; R. Goudsmith; M. Ek; A.E.R.Kr. von dem Borne; M.H.J. van Oers; J 📂 Article 📅 1995 🏛 The Lancet 🌐 English ⚖ 583 KB

The role of the iminosugarN-butyldeoxyno

✍ T. M. Cox; J. M. F. G. Aerts; G. Andria; M. Beck; N. Belmatoug; B. Bembi; R. Che 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 140 KB

The outcome of clinical parameters in ad

✍ Callum Wilson; Ruth Spearing; Lochie Teague; Patsy Robertson; Hilary Blacklock 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 144 KB